ClinicalTrials.gg
CompletedNCT00139776Updated Mar 29, 2021Results posted

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

A Phase 4 interventional study of Celecoxib and Celecoxib in Osteoarthritis, Knee and Osteoarthritis, Hip, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 124 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
875
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
Largest of 14
875 · median 216
Started
2005
the only one that year
Phase 4
10 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
6 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one has the largest enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.

Osteoarthritis, Knee

3,296 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.

03

Conditions studied

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip

Keywords

  • Chronic treatment osteoarthritis, Celecoxib, Continuous Use, Intermittent Use
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been diagnosed, according to American College of Rheumatology guidelines, with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone telephone.

Exclusion criteria

Exclusion Criteria:

  • Subject has had surgery on index joint.
  • Subject has history of rheumatoid arthritis or fibromyalgia syndrome.
  • Subject has active gastrointestinal or cardiovascular disease.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
875 participants (actual)

Study arms

  • Active comparator
    Celecoxib - Continuous use

    Drug: Celecoxib

  • Active comparator
    Celecoxib - Intermittent use

    Drug: Celecoxib

Interventions

  • 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily. Placebo used as flare medication when directed.

  • 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.

06

What researchers measure

Primary outcomes

  1. Number of Flare Events Per Time of Exposure to Study Medication

    Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.

    Time frame: Period III (22 weeks)

Secondary outcomes

  1. Time to Occurrence of First Osteoarthritis (OA) Flare

    Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system

    Time frame: Period III (22 weeks)

  2. Proportion of Days Free From Osteoarthritis (OA) Flare

    Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.

    Time frame: Period III (22 weeks)

  3. Proportion of Days in Osteoarthritis (OA) Flare

    Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.

    Time frame: Period III (22 weeks)

  4. Arthritis Pain Numerical Rating Scale (NRS)

    Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.

    Time frame: Period III

  5. Patient's Global Assessment of Arthritis

    Participant's response to question "Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?" on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.

    Time frame: Period III

  6. Physician's Global Assessment of Arthritis at Final Visit

    Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).

    Time frame: Period III (22 weeks)

  7. Total Rescue Medication Taken (Mean)

    Total amount of rescue medication (acetaminophen in milligrams \[mg\]) taken per month per participant

    Time frame: Period III (22 weeks)

  8. Proportion of Days on Rescue Medication

    Days on rescue medication divided by number of days on study medication in Period III

    Time frame: Period III (22 weeks)

  9. Days on Flare Medication

    Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III

    Time frame: Period III (22 weeks)

  10. Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores

    Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.

    Time frame: Period III (22 weeks)

  11. Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores

    WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.

    Time frame: Period III (22 weeks)

Other outcomes

  1. Change in Medical Outcomes Study Sleep Scale - All Assessments

    Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.

    Time frame: Period III

  2. Medical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep

    Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III

    Time frame: Period III

  3. Change in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments

    SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.

    Time frame: Period III

  4. Serious Adverse Events in Open Label run-in Period

    Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily

    Time frame: 2 weeks prior to double blind dosing

07

Results

Posted May 19, 2009

Participant flow

111 centers in the Americas and Europe enrolled and treated subjects (2 centers in Belgium, 4 centers in Brazil, 20 centers in Canada, 5 centers in Chile, 5 centers in Columbia, 1 center in France, 15 centers in the United Kingdom, and 59 centers in the United States).

Period I
Participant flow — Period I
MilestoneWash-Out: Discontinue Non-Steroidal Anti-InflammatoriesOpen-Label Celecoxib Run-in PeriodCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Started1772000
Completed1197000
Not completed575000
Withdrew: Did not enter period ii575000
Period II
Participant flow — Period II
MilestoneWash-Out: Discontinue Non-Steroidal Anti-InflammatoriesOpen-Label Celecoxib Run-in PeriodCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Started0119700
Completed087500
Not completed032200
Withdrew: Not randomized into period iii032200
Period III
Participant flow — Period III
MilestoneWash-Out: Discontinue Non-Steroidal Anti-InflammatoriesOpen-Label Celecoxib Run-in PeriodCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Started00431427
Completed00355321
Not completed0076106
Withdrew: Adverse event002223
Withdrew: Other002334
Withdrew: Lack of efficacy001024
Withdrew: Lost to follow-up0054
Withdrew: Withdrawal by subject001621

Outcome measures

PrimaryNumber of Flare Events Per Time of Exposure to Study Medication

Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.

Time frame:
Period III (22 weeks)
Reported as:
Mean · flare events per month
Number of Flare Events Per Time of Exposure to Study Medication
flare events per monthCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Number of Flare Events Per Time of Exposure to Study Medication0.54 ± 0.740.93 ± 1.01
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryTime to Occurrence of First Osteoarthritis (OA) Flare

Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system

Time frame:
Period III (22 weeks)
Reported as:
Median · days
Time to Occurrence of First Osteoarthritis (OA) Flare
daysCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Time to Occurrence of First Osteoarthritis (OA) Flare16.0 (14.0 to 22.0)8.0 (8.0 to 9.0)
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · Log Rank · p = <0.0001 (Threshold for statistical significance p\<0.05)
SecondaryProportion of Days Free From Osteoarthritis (OA) Flare

Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.

Time frame:
Period III (22 weeks)
Reported as:
Mean · proportion of days free from OA flare
Proportion of Days Free From Osteoarthritis (OA) Flare
proportion of days free from OA flareCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Proportion of Days Free From Osteoarthritis (OA) Flare0.77 ± 0.280.67 ± 0.30
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryProportion of Days in Osteoarthritis (OA) Flare

Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.

Time frame:
Period III (22 weeks)
Reported as:
Mean · proportion of days in OA flare
Proportion of Days in Osteoarthritis (OA) Flare
proportion of days in OA flareCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Proportion of Days in Osteoarthritis (OA) Flare0.23 ± 0.280.33 ± 0.30
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryArthritis Pain Numerical Rating Scale (NRS)

Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.

Time frame:
Period III
Reported as:
Least squares mean · scores on a scale * weeks
Arthritis Pain Numerical Rating Scale (NRS)
scores on a scale * weeksCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Week 4 (n=415 cont; n=414 inter)81.7 ± 1.190.5 ± 1.1
Week 8 (n=401 cont; n=395 inter)148.8 ± 2.6167.0 ± 2.6
Week 12 (n=383 cont; n=363 inter)212.6 ± 4.1234.3 ± 4.1
Week 16 (n=373 cont; n=339 inter)272.7 ± 5.9297.6 ± 5.9
Week 20 (n=362; n=323 inter)335.9 ± 7.8361.1 ± 7.8
Week 24 (n=350 cont; n=403 inter)378.1 ± 9.1403.9 ± 9.2
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.003 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.022 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.047 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
SecondaryPatient's Global Assessment of Arthritis

Participant's response to question "Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?" on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.

Time frame:
Period III
Reported as:
Least squares mean · scores on a scale * weeks
Patient's Global Assessment of Arthritis
scores on a scale * weeksCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Week 4 (n=415 cont; n=414 inter)67.9 ± 0.6871.7 ± 0.69
Week 8 (n=401 cont; n=395 inter)126.0 ± 1.55133.2 ± 1.56
Week 12 (n=383 cont; n=363 inter)182.8 ± 2.48188.7 ± 2.48
Week 16 (n=373 cont; n=339 inter)236.3 ± 3.59241.2 ± 3.59
Week 20 (n=362 cont; n=323 inter)292.4 ± 4.83293.8 ± 4.84
Week 24 (n=350 cont; n=309 inter)329.2 ± 5.75328.9 ± 5.76
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.096 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.338 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.832 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.972 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
SecondaryPhysician's Global Assessment of Arthritis at Final Visit

Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).

Time frame:
Period III (22 weeks)
Reported as:
Number · participants
Physician's Global Assessment of Arthritis at Final Visit
participantsCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Grade 1 (very good)6839
Grade 2 (good)242244
Grade 3 (fair)91113
Grade 4 (poor)2327
Grade 5 (very poor)22
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · Cochran-Mantel-Haenszel · p = 0.0046 (Overall p-value Threshold for statistical significance p\<0.05)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
SecondaryTotal Rescue Medication Taken (Mean)

Total amount of rescue medication (acetaminophen in milligrams \[mg\]) taken per month per participant

Time frame:
Period III (22 weeks)
Reported as:
Mean · mg taken per month per participant
Total Rescue Medication Taken (Mean)
mg taken per month per participantCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Total Rescue Medication Taken (Mean)1566 ± 48402428 ± 4974
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = 0.0102 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryProportion of Days on Rescue Medication

Days on rescue medication divided by number of days on study medication in Period III

Time frame:
Period III (22 weeks)
Reported as:
Mean · proportion of days
Proportion of Days on Rescue Medication
proportion of daysCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Proportion of Days on Rescue Medication0.044 ± 0.1020.069 ± 0.121
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = 0.0012 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryDays on Flare Medication

Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III

Time frame:
Period III (22 weeks)
Reported as:
Mean · days on medication per month per subject
Days on Flare Medication
days on medication per month per subjectCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Days on Flare Medication6.589 ± 8.5899.793 ± 9.253
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect
SecondaryChange in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores

Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.

Time frame:
Period III (22 weeks)
Reported as:
Least squares mean · scores on a scale
Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores
scores on a scaleCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Total WOMAC score1.60 ± 0.714.99 ± 0.71
WOMAC pain subscale0.37 ± 0.151.18 ± 0.15
WOMAC stiffness subscale0.12 ± 0.070.40 ± 0.07
WOMAC physical function subscale1.13 ± 0.513.43 ± 0.51
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use · Mean difference (final values): 1.60 · 95% CI 0.21 to 2.99Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Intermittent Use · Mean difference (final values): 4.99 · 95% CI 3.60 to 6.38Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use · Mean difference (final values): 0.37 · 95% CI 0.06 to 0.67Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Intermittent Use · Mean difference (final values): 1.18 · 95% CI 0.88 to 1.49Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.004 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use · Mean difference (final values): 0.12 · 95% CI -0.02 to 0.25Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Intermittent Use · Mean difference (final values): 0.40 · 95% CI 0.26 to 0.53Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.002 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use · Mean difference (final values): 1.13 · 95% CI 0.13 to 2.14Change in LSmean (score at end of Period III minus score at start of Period III)
  • Celecoxib 200mg Intermittent Use · Mean difference (final values): 3.43 · 95% CI 2.42 to 4.43Change in LSmean (score at end of Period III minus score at start of Period III)
Other pre-specifiedChange in Medical Outcomes Study Sleep Scale - All Assessments

Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.

Time frame:
Period III
Reported as:
Mean · scores on a scale
Change in Medical Outcomes Study Sleep Scale - All Assessments
scores on a scaleCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Sleep disturbance (n=415 cont; n=410 inter)0.5 ± 15.95-1.4 ± 15.55
Snoring (n=415 cont; n=412 inter)0.9 ± 22.360.7 ± 21.73
Awaken short of breath (n=417 cont; n=411 inter)1.9 ± 16.141.1 ± 20.00
Quantity of sleep (n=417 cont; n=413 inter)-0.1 ± 0.91-0.1 ± 0.89
Sleep adequacy (n=416 cont; n=413 inter)0.1 ± 24.47-1.3 ± 22.26
Somnolence (n=416 cont; n=413 inter)1.4 ± 14.550.6 ± 13.70
Sleep problems index I (n=416 cont; n=410 inter)0.9 ± 13.200.5 ± 13.18
Sleep problems index II (n=413 cont; n=408 inter)0.7 ± 12.29-0.1 ± 12.14
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.2712 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.8737 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.7703 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.3769 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.4075 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.5854 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.8358 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.5878 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
SecondaryArea Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores

WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.

Time frame:
Period III (22 weeks)
Reported as:
Mean · scores on a scale * weeks
Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores
scores on a scale * weeksCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Total WOMAC score604.9 ± 313.10693.6 ± 317.30
WOMAC pain subscale119.2 ± 63.36138.4 ± 65.95
WOMAC stiffness subscale54.5 ± 27.5762.1 ± 27.7
WOMAC physical function subscale431.4 ± 229.38493.6 ± 230.74
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
Other pre-specifiedMedical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep

Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III

Time frame:
Period III
Reported as:
Number · participants
Medical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep
participantsCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Optimal (all scores are 1)139123
Mixed (scores are both 1 and 0)166165
Not optimal (all scores are 0)115132
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · Cochran-Mantel-Haenszel · p = 0.1437 (Threshold for statistical significance p\<0.05)by general association
Other pre-specifiedChange in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments

SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.

Time frame:
Period III
Reported as:
Mean · scores on a scale
Change in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments
scores on a scaleCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
Physical function (n=417 cont; n=413 inter)1.8 ± 23.03-3.2 ± 22.77
Role physical (n=416 cont; n=412 inter)3.5 ± 19.93-1.1 ± 20.07
Bodily pain (n=417 cont; n=414 inter)3.8 ± 20.11-0.3 ± 21.56
General health (n=417 cont; n=414 inter)-0.3 ± 17.60-0.8 ± 17.27
Vitality (n=416 cont; n=414 inter)0.3 ± 20.43-3.5 ± 18.34
Social functioning (n=416 cont; n=414 inter)-1.9 ± 20.16-3.5 ± 22.37
Role emotional (n=417 cont; n=413 inter)-0.7 ± 18.62-2.1 ± 19.80
Mental health (n=416 cont; n=413 inter)-0.9 ± 15.57-1.3 ± 16.05
Physical component summary(n=416 cont;n=411 inter)9.0 ± 55.55-5.2 ± 57.48
Mental component summary (n=416 cont;n=411 inter)-3.1 ± 51.59-10.5 ± 55.66
Statistical analysis
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.3097 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.0139 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.1303 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.1404 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.4015 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = <0.0001 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
  • Celecoxib 200mg Continuous Use vs Celecoxib 200mg Intermittent Use · ANCOVA · p = 0.0301 (Threshold for statistical significance p\<0.05)Treatment as fixed effect and baseline as covariate
Other pre-specifiedSerious Adverse Events in Open Label run-in Period

Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily

Time frame:
2 weeks prior to double blind dosing
Reported as:
Number · participants
Serious Adverse Events in Open Label run-in Period
participantsCelecoxib 200mg Open Label
Anaemia1
Vitreous haemorrhage1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib 200mg Continuous Use———
Celecoxib 200mg Intermittent Use———
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
OsteoarthritisMusculoskeletal and connective tissue disorders0/4312/427
Abdominal painGastrointestinal disorders0/4311/427
GastritisGastrointestinal disorders0/4311/427
PancreatitisGastrointestinal disorders0/4311/427
Chest painGeneral disorders1/4311/427
Non-cardiac chest painGeneral disorders0/4311/427
Skin lacerationInjury, poisoning and procedural complications0/4311/427
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4311/427
Transient ischaemic attackNervous system disorders0/4311/427
Bipolar I disorderPsychiatric disorders0/4311/427
Most frequent other events
Showing 10 of 329
Most frequent other events
EventCelecoxib 200mg Continuous UseCelecoxib 200mg Intermittent Use
HeadacheNervous system disorders65/43168/427
Back painMusculoskeletal and connective tissue disorders20/43131/427
ArthralgiaMusculoskeletal and connective tissue disorders17/43125/427
Pain in extremityMusculoskeletal and connective tissue disorders18/43121/427
NasopharyngitisInfections and infestations19/43120/427
Upper respiratory tract infectionInfections and infestations14/43119/427
DiarrhoeaGastrointestinal disorders7/43117/427
DyspepsiaGastrointestinal disorders17/4316/427
HypertensionVascular disorders9/43113/427
Oedema peripheralGeneral disorders4/43112/427

Baseline characteristics

Age, Continuous
Age, Continuous(years)Celecoxib 200mg Continuous UseCelecoxib 200mg Intermittent UseTotal
Mean58.5 ± 10.0058.7 ± 9.658.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Celecoxib 200mg Continuous UseCelecoxib 200mg Intermittent UseTotal
Female317303620
Male114124238
08

Study locations

124 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Peoria, Arizona 85381, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92646, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    Stockton, California 95204, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Walnut Creek, California 94598, United States
  • Pfizer Investigational Site
    Whittier, California 90601, United States
  • Pfizer Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • Pfizer Investigational Site
    Danbury, Connecticut 06810, United States
  • Pfizer Investigational Site
    New Milford, Connecticut 06776, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Palm Harbor, Florida 34684, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614-7118, United States
  • Pfizer Investigational Site
    Zephyrhills, Florida 33542, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62704, United States
  • Pfizer Investigational Site
    Dubuque, Iowa 52001-7313, United States
  • Pfizer Investigational Site
    Dubuque, Iowa 52002, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40509, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21218, United States
  • Pfizer Investigational Site
    Clinton, Maryland 20735, United States
  • Pfizer Investigational Site
    Frederick, Maryland 21702, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Wheaton, Maryland 20902, United States
  • Pfizer Investigational Site
    Brockton, Massachusetts 02301, United States
  • Pfizer Investigational Site
    Jefferson City, Missouri 65101, United States
  • Pfizer Investigational Site
    Jefferson City, Missouri 65109, United States
  • Pfizer Investigational Site
    Springfield, Missouri 65807, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68516, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68134, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89106, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89144, United States
  • Pfizer Investigational Site
    Great Neck, New York 11021, United States
  • Pfizer Investigational Site
    Manlius, New York 13104, United States
  • Pfizer Investigational Site
    Mineola, New York 11501, United States
  • Pfizer Investigational Site
    New York, New York 10022-1009, United States
  • Pfizer Investigational Site
    Rochester, New York 14609, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103-4019, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44122, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210-1228, United States
  • Pfizer Investigational Site
    Zanesville, Ohio 43701, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Pfizer Investigational Site
    Camp Hill, Pennsylvania 17011, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635-0909, United States
  • Pfizer Investigational Site
    Johnstown, Pennsylvania 15904, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19152, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37601, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920, United States
  • Pfizer Investigational Site
    New Tazewell, Tennessee 37825, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    Arlington, Virginia 22205, United States
  • Pfizer Investigational Site
    Renton, Washington 98055, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Yakima, Washington 98902-4876, United States
  • Pfizer Investigational Site
    Yakima, Washington 98902, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Pfizer Investigational Site
    Ham, 3945, Belgium
  • Pfizer Investigational Site
    Liege, 4000, Belgium
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-903, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90610-000, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13073-350, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04027-000, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T2S 2S7, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5K 1K3, Canada
  • Pfizer Investigational Site
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Pfizer Investigational Site
    St. John's, Newfoundland and Labrador A1E 2C2, Canada
  • Pfizer Investigational Site
    St. John's, Newfoundland and Labrador A1E 2E2, Canada
  • Pfizer Investigational Site
    Corunna, Ontario N0N 1G0, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • Pfizer Investigational Site
    London, Ontario N6C 5J1, Canada
  • Pfizer Investigational Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Pfizer Investigational Site
    North York, Ontario M3M 3E5, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8X 5A6, Canada
  • Pfizer Investigational Site
    Charlottetown, Prince Edward Island C1A 5Y9, Canada
  • Pfizer Investigational Site
    Montague, Prince Edward Island C0A 1R0, Canada
  • Pfizer Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H4N 2W2, Canada
  • Pfizer Investigational Site
    Rimouski, Quebec G5L 9A8, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Pfizer Investigational Site
    Ste-Foy, Quebec G1W 4R4, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Pfizer Investigational Site
    Santiago, RM, Chile
  • Pfizer Investigational Site
    Viña Del Mar, V Region, Chile
  • Pfizer Investigational Site
    Rancagua, VI Región, Chile
  • Pfizer Investigational Site
    Bogota, Cundinamarca, Colombia
  • Pfizer Investigational Site
    Barranquila, Colombia
  • Pfizer Investigational Site
    Bogota, Colombia

Showing the first 100 of 124 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, Immitt J. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1. PubMed 22045833 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Jul 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
May 19, 2009
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00139776
Responsible party
Sponsor
First posted
Aug 31, 2005
Start date
Jul 2005
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
May 19, 2009
Last update
Mar 29, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion